Switch to:
Also traded in: Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.04
TMO's Cash to Debt is ranked lower than
97% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TMO: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
TMO' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.43 Max: 2.34
Current: 0.04
0.04
2.34
Equity to Asset 0.52
TMO's Equity to Asset is ranked lower than
64% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TMO: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
TMO' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.56 Max: 0.75
Current: 0.52
0.31
0.75
Interest Coverage 5.63
TMO's Interest Coverage is ranked lower than
81% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. TMO: 5.63 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 4.66  Med: 7.06 Max: 14.24
Current: 5.63
4.66
14.24
F-Score: 7
Z-Score: 2.48
M-Score: -2.55
WACC vs ROIC
7.94%
7.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 13.77
TMO's Operating margin (%) is ranked higher than
86% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. TMO: 13.77 )
Ranked among companies with meaningful Operating margin (%) only.
TMO' s Operating margin (%) Range Over the Past 10 Years
Min: 6.38  Med: 11.12 Max: 14.82
Current: 13.77
6.38
14.82
Net-margin (%) 11.64
TMO's Net-margin (%) is ranked higher than
84% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. TMO: 11.64 )
Ranked among companies with meaningful Net-margin (%) only.
TMO' s Net-margin (%) Range Over the Past 10 Years
Min: 4.46  Med: 9.38 Max: 11.51
Current: 11.64
4.46
11.51
ROE (%) 9.55
TMO's ROE (%) is ranked higher than
70% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. TMO: 9.55 )
Ranked among companies with meaningful ROE (%) only.
TMO' s ROE (%) Range Over the Past 10 Years
Min: 2.02  Med: 7.23 Max: 10.13
Current: 9.55
2.02
10.13
ROA (%) 4.73
TMO's ROA (%) is ranked higher than
71% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. TMO: 4.73 )
Ranked among companies with meaningful ROA (%) only.
TMO' s ROA (%) Range Over the Past 10 Years
Min: 1.32  Med: 4.49 Max: 5.7
Current: 4.73
1.32
5.7
ROC (Joel Greenblatt) (%) 48.15
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. TMO: 48.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TMO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.16  Med: 41.38 Max: 62.95
Current: 48.15
16.16
62.95
Revenue Growth (3Y)(%) 11.80
TMO's Revenue Growth (3Y)(%) is ranked higher than
71% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. TMO: 11.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TMO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.9  Med: 8.10 Max: 18.7
Current: 11.8
-12.9
18.7
EBITDA Growth (3Y)(%) 23.40
TMO's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. TMO: 23.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TMO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30  Med: 13.95 Max: 40.8
Current: 23.4
-30
40.8
EPS Growth (3Y)(%) 21.00
TMO's EPS Growth (3Y)(%) is ranked higher than
81% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TMO: 21.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TMO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.3  Med: 12.15 Max: 74.6
Current: 21
-41.3
74.6
» TMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

TMO Guru Trades in Q1 2015

Caxton Associates 30,000 sh (New)
Mario Gabelli 23,315 sh (+79.35%)
Paul Tudor Jones 8,461 sh (+77.64%)
Jim Simons 250,144 sh (+21.05%)
PRIMECAP Management 5,168,990 sh (+15.20%)
Pioneer Investments 2,138,986 sh (+8.85%)
John Rogers 586,411 sh (+1.02%)
Ruane Cunniff 2,873 sh (unchged)
Eric Mindich 1,563,000 sh (unchged)
Caxton Associates 40,000 sh (unchged)
Vanguard Health Care Fund 2,179,000 sh (unchged)
First Eagle Investment 200 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Scott Black 74,759 sh (-0.14%)
Signature Select Canadian Fund 121,000 sh (-1.31%)
Mairs and Power 2,381 sh (-2.66%)
Dodge & Cox 53,802 sh (-4.27%)
David Dreman 15,282 sh (-4.39%)
First Pacific Advisors 3,410,800 sh (-5.71%)
Steven Romick 3,180,000 sh (-5.95%)
John Griffin 1,950,000 sh (-7.80%)
Andreas Halvorsen 3,531,837 sh (-38.96%)
Larry Robbins 6,910,771 sh (-39.31%)
» More
Q2 2015

TMO Guru Trades in Q2 2015

Ray Dalio 43,723 sh (New)
Steven Cohen 33,300 sh (New)
Larry Robbins 9,259,710 sh (+33.99%)
Vanguard Health Care Fund 2,679,000 sh (+22.95%)
Mario Gabelli 26,450 sh (+13.45%)
PRIMECAP Management 5,520,640 sh (+6.80%)
Pioneer Investments 2,171,128 sh (+1.50%)
First Pacific Advisors 3,448,400 sh (+1.10%)
Ruane Cunniff 2,873 sh (unchged)
Dodge & Cox 53,802 sh (unchged)
Steven Romick 3,180,000 sh (unchged)
First Eagle Investment 200 sh (unchged)
Caxton Associates Sold Out
Eric Mindich Sold Out
Paul Tudor Jones Sold Out
John Rogers 585,261 sh (-0.20%)
Mairs and Power 2,335 sh (-1.93%)
David Dreman 14,632 sh (-4.25%)
Scott Black 60,041 sh (-19.69%)
Jim Simons 188,344 sh (-24.71%)
John Griffin 1,190,000 sh (-38.97%)
Andreas Halvorsen 207,527 sh (-94.12%)
» More
Q3 2015

TMO Guru Trades in Q3 2015

Paul Tudor Jones 5,500 sh (New)
John Burbank 27,500 sh (New)
Manning & Napier Advisors, Inc 504,380 sh (New)
Vanguard Health Care Fund 3,081,000 sh (+15.01%)
John Rogers 607,166 sh (+3.74%)
Pioneer Investments 2,196,122 sh (+1.15%)
First Eagle Investment 200 sh (unchged)
Ruane Cunniff 2,873 sh (unchged)
Andreas Halvorsen Sold Out
Jim Simons Sold Out
Dodge & Cox 52,902 sh (-1.67%)
PRIMECAP Management 5,401,253 sh (-2.16%)
Scott Black 58,434 sh (-2.68%)
David Dreman 14,000 sh (-4.32%)
Larry Robbins 8,511,204 sh (-8.08%)
John Griffin 1,090,000 sh (-8.40%)
Signature Select Canadian Fund 104,800 sh (-13.39%)
Mairs and Power 1,885 sh (-19.27%)
Ray Dalio 30,504 sh (-30.23%)
Mario Gabelli 16,450 sh (-37.81%)
First Pacific Advisors 1,933,550 sh (-43.93%)
Steven Romick 1,774,700 sh (-44.19%)
Steven Cohen 1,800 sh (-94.59%)
» More
Q4 2015

TMO Guru Trades in Q4 2015

Ken Fisher 1,867 sh (New)
Vanguard Health Care Fund 3,081,000 sh (unchged)
Mario Gabelli 16,165 sh (-1.73%)
Steven Romick 1,638,180 sh (-7.69%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc. - May 07, 2014

In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

Mindich Continues Pattern of Selling More Stakes Than He Buys Lorillard tops list of stakes Mindich sells in second quarter
In 2004, Eric Mindich (Trades, Portfolio) oversaw the launch of Eton Park Capital Management, one of the largest in history at $3.5 billion. He still does things in a big way. His quarterly pattern has been to buy and sell stakes in roughly equal proportions, but the second quarter of 2015 was a little bit different. He continued, for the third straight quarter, to sell about half again as many stakes as he bought. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.60
TMO's P/E(ttm) is ranked higher than
62% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.16 vs. TMO: 25.60 )
Ranked among companies with meaningful P/E(ttm) only.
TMO' s P/E(ttm) Range Over the Past 10 Years
Min: 11.09  Med: 24.28 Max: 62.79
Current: 25.6
11.09
62.79
Forward P/E 14.12
TMO's Forward P/E is ranked higher than
74% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.18 vs. TMO: 14.12 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.50
TMO's PE(NRI) is ranked higher than
62% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.30 vs. TMO: 25.50 )
Ranked among companies with meaningful PE(NRI) only.
TMO' s PE(NRI) Range Over the Past 10 Years
Min: 13.48  Med: 24.87 Max: 62.07
Current: 25.5
13.48
62.07
P/B 2.34
TMO's P/B is ranked higher than
57% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. TMO: 2.34 )
Ranked among companies with meaningful P/B only.
TMO' s P/B Range Over the Past 10 Years
Min: 0.83  Med: 1.59 Max: 2.73
Current: 2.34
0.83
2.73
P/S 3.00
TMO's P/S is ranked lower than
62% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. TMO: 3.00 )
Ranked among companies with meaningful P/S only.
TMO' s P/S Range Over the Past 10 Years
Min: 1.25  Med: 2.19 Max: 3.47
Current: 3
1.25
3.47
PFCF 24.08
TMO's PFCF is ranked higher than
56% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.86 vs. TMO: 24.08 )
Ranked among companies with meaningful PFCF only.
TMO' s PFCF Range Over the Past 10 Years
Min: 10.22  Med: 20.13 Max: 31.05
Current: 24.08
10.22
31.05
POCF 19.82
TMO's POCF is ranked higher than
50% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.82 vs. TMO: 19.82 )
Ranked among companies with meaningful POCF only.
TMO' s POCF Range Over the Past 10 Years
Min: 8.72  Med: 17.11 Max: 25.64
Current: 19.82
8.72
25.64
EV-to-EBIT 28.63
TMO's EV-to-EBIT is ranked lower than
69% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.94 vs. TMO: 28.63 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.9  Med: 21.10 Max: 64.9
Current: 28.63
10.9
64.9
EV-to-EBITDA 16.55
TMO's EV-to-EBITDA is ranked lower than
61% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.63 vs. TMO: 16.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
TMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 13.60 Max: 32.6
Current: 16.55
6.7
32.6
PEG 1.40
TMO's PEG is ranked higher than
81% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. TMO: 1.40 )
Ranked among companies with meaningful PEG only.
TMO' s PEG Range Over the Past 10 Years
Min: 0.54  Med: 1.92 Max: 66.49
Current: 1.4
0.54
66.49
Shiller P/E 42.44
TMO's Shiller P/E is ranked lower than
61% of the 44 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.69 vs. TMO: 42.44 )
Ranked among companies with meaningful Shiller P/E only.
TMO' s Shiller P/E Range Over the Past 10 Years
Min: 20.68  Med: 38.48 Max: 62.08
Current: 42.44
20.68
62.08
Current Ratio 1.05
TMO's Current Ratio is ranked lower than
87% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. TMO: 1.05 )
Ranked among companies with meaningful Current Ratio only.
TMO' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.36 Max: 3.83
Current: 1.05
0.9
3.83
Quick Ratio 0.70
TMO's Quick Ratio is ranked lower than
91% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. TMO: 0.70 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.67 Max: 3.4
Current: 0.7
0.61
3.4
Days Inventory 77.76
TMO's Days Inventory is ranked higher than
57% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. TMO: 77.76 )
Ranked among companies with meaningful Days Inventory only.
TMO' s Days Inventory Range Over the Past 10 Years
Min: 65.13  Med: 69.62 Max: 125.07
Current: 77.76
65.13
125.07
Days Sales Outstanding 54.75
TMO's Days Sales Outstanding is ranked higher than
64% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. TMO: 54.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.89  Med: 53.81 Max: 134.07
Current: 54.75
50.89
134.07
Days Payable 31.40
TMO's Days Payable is ranked lower than
74% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. TMO: 31.40 )
Ranked among companies with meaningful Days Payable only.
TMO' s Days Payable Range Over the Past 10 Years
Min: 31.3  Med: 32.75 Max: 103.55
Current: 31.4
31.3
103.55

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.48
TMO's Dividend Yield is ranked lower than
89% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. TMO: 0.48 )
Ranked among companies with meaningful Dividend Yield only.
TMO' s Dividend Yield Range Over the Past 10 Years
Min: 0.22  Med: 0.50 Max: 0.86
Current: 0.48
0.22
0.86
Dividend Payout 0.12
TMO's Dividend Payout is ranked higher than
94% of the 51 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. TMO: 0.12 )
Ranked among companies with meaningful Dividend Payout only.
TMO' s Dividend Payout Range Over the Past 10 Years
Min: 0.1  Med: 0.16 Max: 0.22
Current: 0.12
0.1
0.22
Forward Dividend Yield 0.48
TMO's Forward Dividend Yield is ranked lower than
90% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.49 vs. TMO: 0.48 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.47
TMO's Yield on cost (5-Year) is ranked lower than
92% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.58 vs. TMO: 0.47 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TMO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.22  Med: 0.50 Max: 0.86
Current: 0.47
0.22
0.86
3-Year Average Share Buyback Ratio -1.50
TMO's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.80 vs. TMO: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.3  Med: -0.10 Max: 4.6
Current: -1.5
-38.3
4.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.55
TMO's Price/Projected FCF is ranked higher than
64% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. TMO: 1.55 )
Ranked among companies with meaningful Price/Projected FCF only.
TMO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.74  Med: 1.54 Max: 43.46
Current: 1.55
0.74
43.46
Price/DCF (Earnings Based) 1.20
TMO's Price/DCF (Earnings Based) is ranked higher than
76% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.79 vs. TMO: 1.20 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.36
TMO's Price/Median PS Value is ranked lower than
81% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. TMO: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
TMO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 0.86 Max: 1.46
Current: 1.36
0.27
1.46
Price/Peter Lynch Fair Value 1.34
TMO's Price/Peter Lynch Fair Value is ranked higher than
73% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.93 vs. TMO: 1.34 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
TMO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.59  Med: 1.80 Max: 14.2
Current: 1.34
0.59
14.2
Earnings Yield (Greenblatt) (%) 3.50
TMO's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. TMO: 3.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TMO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 4.70 Max: 9.2
Current: 3.5
1.5
9.2
Forward Rate of Return (Yacktman) (%) 22.38
TMO's Forward Rate of Return (Yacktman) (%) is ranked higher than
82% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. TMO: 22.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TMO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.6  Med: 16.70 Max: 31.5
Current: 22.38
-2.6
31.5

More Statistics

Revenue(Mil) $16965
EPS $ 4.91
Beta0.97
Short Percentage of Float1.56%
52-Week Range $117.10 - 143.65
Shares Outstanding(Mil)399.10

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 17,565 18,496 19,020
EPS($) 8.12 8.88 9.95
EPS without NRI($) 8.12 8.88 9.95

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, COO, ISRG » details
Traded in other countries:TN8.Germany, TMO.Mexico, TFS.Switzerland,
Thermo Fisher Scientific Inc is a Delaware corporation and was incorporated in 1956. The Company completed its initial public offering in 1967 and was listed on the New York Stock Exchange in 1980. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It serves more than 400,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company serves their customers through four brands, Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to
» More Articles for TMO

Headlines

Articles On GuruFocus.com
Steven Romick Sells Microsoft, Walgreens, CVS Jan 20 2016 
Weekly 52-Week Highs Highlight: Kroger Co., Harris Corporation, Thermo Fisher Scientific, Delhaize G Dec 26 2015 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
First Pacific Advisors Slashes Stake in CVS Health Dec 17 2015 
Health Care Stocks Play Prominent Roles in Steven Romick's Transactions Dec 15 2015 
Steven Romick Sells CVS, Buys United Technologies Oct 27 2015 
Mindich Continues Pattern of Selling More Stakes Than He Buys Sep 15 2015 
Moody Lynn & Lieberson Top Buys in Second Quarter Aug 27 2015 
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Steven Romick Sells Stakes in 4 Companies Jul 01 2015 

More From Other Websites
Finding Value in These Names -- Agilent Technologies, Exact Sciences, Thermo Fisher Scientific, and... Feb 08 2016
[$$] Thermo Fisher's Allure Feb 06 2016
Seeking Value, Growth and Momentum - Analyst Notes on Delta Air Lines, E I du Pont de Nemours,... Feb 05 2016
Thermo Fisher Scientific, Inc. Earnings Analysis: Q4, 2015 By the Numbers Feb 02 2016
How 2 Companies Screwed Up on Guidance Feb 01 2016
Edited Transcript of TMO earnings conference call or presentation 28-Jan-16 1:30pm GMT Jan 28 2016
Thermo Fisher Tops Q4 Earnings, Affymetrix Buy in the Cards Jan 28 2016
Pressure BioSciences' SCIEX Deal Could Dramatically Accelerate Revenue Jan 28 2016
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 28 2016
Thermo Fisher (TMO) Beats on Q4 Earnings, Revenues Jan 28 2016
Q4 2015 Thermo Fisher Scientific Inc Earnings Release - Before Market Open Jan 28 2016
Thermo Fisher tops Street 4Q forecasts Jan 28 2016
Thermo Fisher tops Street 4Q forecasts Jan 28 2016
Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results Jan 28 2016
Thermo Fisher quarterly profit edges past Street estimates Jan 28 2016
Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results Jan 28 2016
Will Thermo Fisher (TMO) Surprise Q4 Earnings Expectations? Jan 26 2016
5 Stocks You Need to Stay Far Away From in This Market Jan 22 2016
Thermo Fisher: Life Technologies Synergy Drive New Buyouts Jan 20 2016
Deutsche Bank Recommends These 8 Health Care Stocks on Market Volatility Jan 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK